CPHI Frankfurt 2022: Global pharma confidence hits record high in CPHI Pharma Index

In fact, the overall CPHI Pharma Index – a collateralised metric of all major ranking categories – has risen by more than 8%, the largest year-on-year gain in the survey’s six year history

Sustaining growth momentum is key for Navin Fluorine: ICICI Securities

NFIL’s ambition is to reach revenues of US$100mn from CDMO by FY25.

Dipharma receives regulatory authorization for the new line at Its cGMP pilot plant

The company increases its efficiency and is able to face the growing demand for its services.

DME market across 7MM set to reach $11.1 billion in 2031, forecasts GlobalData

Bayer chronic kidney disease medication Kerendia can gain quick market penetration in India, says GlobalData

Lonza appoints Daniel Palmacci as President of the Cell & Gene Division

He takes over leadership of Cell & Gene from Jean-Christophe Hyvert, enabling Jean-Christophe to increase his focus on his role as President of the Biologics Division

Yingli Pharma announces first patient dosed in Phase 2 Trial of Linperlisib for peripheral T Cell Lymphoma

Phase 2 study to assess efficacy and safety of once daily linperlisib in patients with advanced peripheral T/NK cell lymphoma

Infosys completes acquisition of BASE life science

The acquisition reaffirms Infosys’ commitment to help global life sciences companies

8th edition of Indo-Japanese Chronic Total Occlusion (IJCTO) summit concluded successfully

The summit to demonstrate revolutionary techniques and advanced medical procedures for treating CTO

NewAmsterdam Pharma shares new data from Phase 2b ROSE Study

82.5% of patients treated at 10mg dose of obicetrapib achieved LDL-c target of <70 mg/dL, compared to 20% of patients treated with placebo